دورية أكاديمية
Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing.
| العنوان: | Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing. |
|---|---|
| المؤلفون: | Modi ME; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Majchrzak MJ; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Fonseca KR; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Doran A; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Osgood S; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Vanase-Frawley M; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Feyfant E; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., McInnes H; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Darvari R; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Buhl DL; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.)., Kablaoui NM; Neuroscience and Pain Research Unit (M.E.M., M.J.M., D.L.B.), Department of Pharmacokinetics, Dynamics and Metabolism (K.R.F.), Global Biotherapeutics Technologies (E.F.), and Worldwide Medicinal Chemistry (N.M.K.), Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts; Department of Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc., Groton, Connecticut (A.D., S.O., M.V.-F.); and Biotherapuetics Pharmaceutical Research and Development, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts (H.M., R.D.) Natasha.M.Kablaoui@pfizer.com. |
| المصدر: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2016 Aug; Vol. 358 (2), pp. 164-72. Date of Electronic Publication: 2016 May 23. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1999- : Bethesda, MD : American Society for Pharmacology and Experimental Therapeutics Original Publication: Baltimore : Williams & Wilkins |
| مواضيع طبية MeSH: | Drug Discovery*, Conditioning, Psychological/*drug effects , Fear/*psychology , Immobility Response, Tonic/*drug effects , Oxytocin/*administration & dosage , Oxytocin/*pharmacology , Peptides, Cyclic/*administration & dosage , Peptides, Cyclic/*pharmacology , Polyethylene Glycols/*administration & dosage , Polyethylene Glycols/*pharmacology , Receptors, Oxytocin/*agonists, Animals ; CHO Cells ; Cricetinae ; Cricetulus ; Drug Administration Routes ; Immobility Response, Tonic/physiology ; Male ; Mice ; Oxytocin/chemistry ; Oxytocin/pharmacokinetics ; Peptides, Cyclic/chemistry ; Peptides, Cyclic/pharmacokinetics ; Polyethylene Glycols/chemistry ; Polyethylene Glycols/pharmacokinetics ; Rats |
| مستخلص: | Oxytocin (OT) modulates the expression of social and emotional behaviors and consequently has been proposed as a pharmacologic treatment of psychiatric diseases, including autism spectrum disorders and schizophrenia; however, endogenous OT has a short half-life in plasma and poor permeability across the blood-brain barrier. Recent efforts have focused on the development of novel drug delivery methods to enhance brain penetration, but few efforts have aimed at improving its half-life. To explore the behavioral efficacy of an OT analog with enhanced plasma stability, we developed PF-06655075 (PF1), a novel non-brain-penetrant OT receptor agonist with increased selectivity for the OT receptor and significantly increased pharmacokinetic stability. PF-06478939 was generated with only increased stability to disambiguate changes to selectivity versus stability. The efficacy of these compounds in evoking behavioral effects was tested in a conditioned fear paradigm. Both central and peripheral administration of PF1 inhibited freezing in response to a conditioned fear stimulus. Peripheral administration of PF1 resulted in a sustained level of plasma concentrations for greater than 20 hours but no detectable accumulation in brain tissue, suggesting that plasma or cerebrospinal fluid exposure was sufficient to evoke behavioral effects. Behavioral efficacy of peripherally administered OT receptor agonists on conditioned fear response opens the door to potential peripheral mechanisms in other behavioral paradigms, whether they are mediated by direct peripheral activation or feed-forward responses. Compound PF1 is freely available as a tool compound to further explore the role of peripheral OT in behavioral response. (Copyright © 2016 The Author(s).) |
| References: | Brain Sci. 2015 Jan 20;5(1):3-13. (PMID: 25612002) Biol Psychiatry. 2009 May 15;65(10):887-92. (PMID: 19246030) Neuron. 2012 Feb 9;73(3):553-66. (PMID: 22325206) Adv Pharmacol. 2004;50:531-92, 655-708. (PMID: 15350270) J Pharm Sci. 2012 Mar;101(3):1327-35. (PMID: 22161810) Mol Psychiatry. 2015 Sep;20(9):1085-90. (PMID: 25349162) Psychoneuroendocrinology. 2014 Jul;45:49-57. (PMID: 24845176) Prog Brain Res. 2008;170:193-204. (PMID: 18655883) Neuropsychopharmacology. 2003 Jan;28(1):193-8. (PMID: 12496956) Endocrinol Exp. 1985 Mar;19(1):29-37. (PMID: 3872788) Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31. (PMID: 19589090) Fundam Clin Pharmacol. 1988;2(3):223-38. (PMID: 3042568) Psychopharmacology (Berl). 2012 Sep;223(2):149-58. (PMID: 22526533) Neurogastroenterol Motil. 2012 Mar;24(3):e136-46. (PMID: 22188490) J Pharmacol Exp Ther. 1987 Apr;241(1):268-74. (PMID: 3572787) Front Neuroendocrinol. 2011 Oct;32(4):426-50. (PMID: 21802441) Trends Neurosci. 2012 Nov;35(11):649-59. (PMID: 22974560) Cell Mol Neurobiol. 2003 Oct;23(4-5):727-38. (PMID: 14514027) Ann N Y Acad Sci. 1993 Jul 22;689:674-6. (PMID: 8373075) Int J Mol Sci. 2014 Feb 27;15(3):3580-95. (PMID: 24583848) Ann N Y Acad Sci. 2008 Dec;1148:415-20. (PMID: 19120136) Behav Brain Res. 2015;287:34-41. (PMID: 25819422) Curr Protoc Neurosci. 2004 Sep;Chapter 8:Unit 8.5C. (PMID: 18428608) Science. 2011 Jul 1;333(6038):104-7. (PMID: 21719680) Prog Brain Res. 2008;170:207-18. (PMID: 18655884) Neuropsychopharmacology. 2011 Nov;36(12):2488-97. (PMID: 21796104) Endocrinology. 1993 Sep;133(3):1239-46. (PMID: 8396014) Macromol Biosci. 2006 Dec 8;6(12):977-90. (PMID: 17128422) J Neuroendocrinol. 1996 Mar;8(3):227-33. (PMID: 8730656) Drug Metab Dispos. 2011 Jul;39(7):1270-7. (PMID: 21474681) J Physiol. 1969 Oct;204(3):653-68. (PMID: 5824107) Pharm Weekbl Sci. 1987 Apr 24;9(2):65-74. (PMID: 3295762) Transl Psychiatry. 2013 May 21;3:e258. (PMID: 23695233) Biol Psychiatry. 2007 Feb 15;61(4):498-503. (PMID: 16904652) Pharmacol Biochem Behav. 1994 Sep;49(1):101-6. (PMID: 7816858) Neurosci Biobehav Rev. 2015 Feb;49:182-92. (PMID: 25526824) Endokrinologie. 1981 Dec;78(2-3):191-204. (PMID: 7333224) Neuroimage. 2009 Oct 1;47(4):1312-8. (PMID: 19362597) Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4389-94. (PMID: 20160081) |
| المشرفين على المادة: | 0 (PF-06655075) 0 (Peptides, Cyclic) 0 (Receptors, Oxytocin) 3WJQ0SDW1A (Polyethylene Glycols) 50-56-6 (Oxytocin) |
| تواريخ الأحداث: | Date Created: 20160525 Date Completed: 20170526 Latest Revision: 20191210 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC4959095 |
| DOI: | 10.1124/jpet.116.232702 |
| PMID: | 27217590 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1521-0103 |
|---|---|
| DOI: | 10.1124/jpet.116.232702 |